ICON Public Limited Company Stock

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-12 EDT 5-day change 1st Jan Change
306 USD -2.05% Intraday chart for ICON Public Limited Company -4.02% +8.10%
Sales 2024 * 8.64B 11.9B Sales 2025 * 9.28B 12.78B Capitalization 25.24B 34.77B
Net income 2024 * 822M 1.13B Net income 2025 * 1.01B 1.39B EV / Sales 2024 * 3.19 x
Net Debt 2024 * 2.34B 3.23B Net Debt 2025 * 1.15B 1.58B EV / Sales 2025 * 2.84 x
P/E ratio 2024 *
32 x
P/E ratio 2025 *
25.8 x
Employees 41,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.34%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.05%
1 week-4.02%
Current month-8.92%
1 month-8.25%
3 months+20.00%
6 months+23.77%
Current year+8.10%
More quotes
1 week
305.43
Extreme 305.43
325.91
1 month
305.43
Extreme 305.43
339.46
Current year
244.59
Extreme 244.59
344.77
1 year
181.92
Extreme 181.92
344.77
3 years
171.43
Extreme 171.43
344.77
5 years
104.28
Extreme 104.275
344.77
10 years
35.33
Extreme 35.33
344.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 11-10-31
Director of Finance/CFO 45 05-12-31
Chairman 61 05-10-02
Members of the board TitleAgeSince
Founder 71 90-05-31
Chief Executive Officer 63 11-10-31
Director/Board Member 68 21-06-30
More insiders
Date Price Change Volume
24-04-12 306 -2.05% 393,747
24-04-11 312.4 -0.04% 198,518
24-04-10 312.5 -2.08% 313,542
24-04-09 319.1 -0.57% 395,580
24-04-08 321 +0.67% 302,613

Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm

More quotes
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
306 USD
Average target price
352.8 USD
Spread / Average Target
+15.29%
Consensus